Cavtat-Dubrovnik, Croatia
More info
News & events
Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009.
September 17, 2009
- Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel, Executive Vice President and Chief Financial Officer, will present the Company to the investors during the MIDCAP event in Paris
- Upon the occasion of the announcement of interim clinical results for IPH 1101 at the ESMO congress on Monday 21, the Company will host a conference call at 2:30pm on that same day (Details to connect to this call will be communicated on monday)
Inserm Transfert and Innate Pharma enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
September 11, 2009
- Over a three-year period, Inserm Transfert will make available to Innate Pharma information on early-stage antibody targets discovered within Inserm’s academic research laboratories, for the purpose of jointly advancing them and concluding commercial licenses.
Financial results for the first half of 2009: significant investment in clinical programs and cash position reinforced
August 31, 2009
- Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates.
- Increase in operational loss, explained notably by the contractual end of the R&D collaboration agreement with Novo Nordisk A/S.
- Cash position reinforced through the early refund of €10.4m in research tax credit; cash runway into 2011.
Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo
August 27, 2009
- Approval by the French regulatory authorities of a first Phase IIa clinical trial with IPH 2101 in patients suffering from Multiple Myeloma, a severe haematological cancer
- Conducted in France, this multicenter trial will be supported by a 2.9 million euros grant from Oséo
- Other Phase IIa trials with IPH 2101 are being planned
Innate Pharma reports positive Phase IIa clinical results for IPH 1101 (γδT cell agonist) in type C viral hepatitis
June 29, 2009
- The primary endpoint of the trial was met
- This is the first proof of concept in patients of an anti-viral effect of γδ T cell activation
- Innate Pharma intends to develop further its program in this indication
Innate Pharma announces today the outcome of its annual general meeting, including changes in the composition of its Supervisory Board
June 23, 2009
- Innate Pharma held its annual general meeting on June 23, 2009
- All proposed resolutions were voted according to management’s recommendations
- Mrs. Irina Staatz-Granzer joins the Supervisory Board as a new, independent member
- Mr. Patrick Van Beneden, from GIMV, an investor, is appointed as observer to the Supervisory Board for a one-year period